Aim: Prior to the discontinuation of bococizumab's clinical development, it was considered advantageous to develop an infrequent dosing regimen (eg, monthly).
| INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in industrialized countries. 1 Epidemiologic studies have shown that hypercholesterolemia, and especially hypercholesterolemia caused by elevated levels of low-density lipoprotein cholesterol (LDL-C), is a direct and strong risk factor for ASCVD. [2] [3] [4] Despite the widespread availability of effective lipid-lowering agents, such as statins, a significant proportion of patients at high risk of ASCVD continue to be managed suboptimally due to insufficient therapeutic efficacy, safety concerns regarding higher doses of statins, and poor compliance. 5, 6 Therefore, there is a medical need for additional lipid-lowering options capable of minimizing the residual cardiovascular risk of patients who display a suboptimal response and/or intolerance to current first-line agents. 7 Bococizumab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] which is a protein that regulates the availability of the LDL receptor (LDLR) expressed predominantly on hepatocytes. Binding of PCSK9 to the LDLR leads to the receptor's internalization for degradation, which ultimately results in elevated circulating levels of LDL-C due to a reduction in LDLR-mediated uptake. [18] [19] [20] By binding to PCSK9 and preventing its interaction with the LDLR, bococizumab and other anti-PCSK9 antibodies are able to prevent LDLR internalization and consequently reduce the level of circulating LDL-C via enhanced receptor-mediated clearance. Phase 2 studies showed bococizumab to be well tolerated and capable of providing substantial reductions in fasting LDL-C levels when administered as single or multiple doses, either alone or against a background of ongoing lipid-lowering therapy. [12] [13] [14] The drug was subsequently investigated in the multinational phase 3 SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events) clinical development program as an add-on therapy for primary hyperlipidemia and mixed dyslipidemia in patients at high and very high risk of cardiovascular events. [15] [16] [17] The dosing regimen investigated in the SPIRE program was a 1.5-mL subcutaneous injection of bococizumab 150 mg every 2 weeks. From a patient compliance and convenience perspective, however, it was also desirable to develop a less frequent dosing regimen. To achieve this goal, we proposed concurrent delivery of bococizumab with recombinant human hyaluronidase (rHuPH20), which is the 61-kDa active ingredient in the commercial product
Hylenex® recombinant (hyaluronidase human injection) and an enzyme that transiently and locally increases the dispersion and absorption of subcutaneously delivered therapeutic agents via degradation of hyaluronan, which is a major glycosaminoglycan constituent of the extracellular matrix. 21, 22 We hypothesized that administering bococizumab in co-mixture with rHuPH20 would enable delivery of a larger volume in a single subcutaneous injection, thus allowing an increase in dose and potentially improving the bioavailability of bococizumab. We further hypothesized that an increase in the bioavailability of bococizumab or the delivery of a higher dose would, in turn, lead to a greater reduction in LDL-C of sufficient magnitude to support a dosing interval less frequent than every 2 weeks.
The aims of the current study were to characterize the pharmacokinetic (PK), pharmacodynamic (PD), and safety profiles of a single subcutaneous dose of bococizumab 150, 300, or 450 mg in co-mixture with rHuPH20, as well as a single subcutaneous dose of bococizumab 300 mg alone, in healthy adult subjects, and to compare the bioavailability and PD effect of bococizumab when administered alone or in co-mixture with rHuPH20.
| MATERIALS AND METHODS

| Study design
This was a phase 1, open-label, single-dose, randomized, dose-escalation study in healthy adult volunteers (http://clinicaltrials. gov identifier: NCT02667223). A total of 60 subjects were randomized equally among 4 dosing groups (15 subjects/group) that received bococizumab 150 mg in co-mixture with 2 kU of rHuPH20 in a total injection volume of 1.2 mL, bococizumab 300 mg in co-mixture with 4 kU of rHuPH20 in a total injection volume of 2.3 mL, bococizumab 450 mg in co-mixture with 6 kU of rHuPH20 in a total injection volume of 3.4 mL, or bococizumab 300 mg in a total injection volume of 2 mL. The clinical study protocol also planned to enroll a dosing group of 15 subjects with hypercholesterolemia and on statin therapy, but this group was not recruited at the sponsor's discretion because prohibitive operational challenges were encountered and because the scientific objectives of the study were adequately addressed without the inclusion of this group.
Complete lists of the inclusion and exclusion criteria for this study are included in the supplementary material. The main inclusion criteria were healthy men and women aged 18 to 65 years, total body weight from 60 to 120 kg and body mass index (BMI) ≤35 kg/m 2 , fasting LDL-C from 70 to 190 mg/dL at both screening visits and with the 2 screening values within 20% of one another, and fasting triglycerides ≤400 mg/dL at the first screening visit.
| Sample size calculations
A total of 15 evaluable subjects in each group were estimated as sufficient to provide 90% confidence intervals (CIs) for intergroup differences of ±0.3795 in the estimated, natural log-transformed, total plasma exposure to bococizumab (AUC inf ) and ±0.3686 in the natural log-transformed, maximal plasma concentration of bococizumab (C max ) with 90% coverage probability. These calculations were based on standard deviation (SD) estimates of 0.525 and 0.510 for AUC inf and C max , respectively, which were obtained from a previous phase 1 study of bococizumab. 11 A total of 15 evaluable subjects in each dosing group were also estimated as sufficient to provide 90% CIs for intergroup differences of ±0.0983 in the natural log-transformed area under the LDL-C concentration-time profile from time zero to Day 85 (AUEC 85 ) and of ±0.2024 in the natural log-transformed maximal reduction in LDL-C (MaxE LDL-C ) with 90% coverage probability. These calculations were based on SD estimates of 0.136 and 0.280 for AUEC 85 and MaxE LDL-C , respectively, which were obtained from the previous phase 1 study of bococizumab mentioned above.
| Study conduct
The study protocol and informed consent documentation were reviewed and approved by the independent ethics committee at the The initial screening of subjects took place 14 to 28 days prior to dosing, with additional screening procedures performed 7 days before dosing. Enrolled subjects were given a unique electronic data capture and management system identification and, prior to dosing, were also allocated a randomization number that was retained throughout the study. Each subject's randomization number corresponded to a treatment schedule determined by a sponsor-generated randomization enzyme-linked immunosorbent assay, which has been described previously. 16 The lower limit of quantification for the assay was 400 ng/mL.
Samples with bococizumab concentrations above the upper limit of quantification (12 800 ng/mL) were adequately diluted into the range of quantification. The overall interassay accuracy, expressed as percent relative error, in the measurement of control samples ranged from 0.625 to 8.36%, and the overall interassay precision, expressed as percent coefficient of variation (%CV) of the mean estimated concentrations of control samples, was ≤6.54%.
| LDL-C analysis
Low-density lipoprotein cholesterol concentrations used to character- 
| Analysis of anti-bococizumab and antirHuPH20 antibodies and nAbs
Titers of bococizumab antidrug antibodies (ADAs) within blood samples were determined by using a semiquantitative electrochemiluminescence immunoassay with a %CV of ≤8.21% for control samples, while anti-bococizumab neutralizing antibodies (nAbs) were measured by using an immunoassay with a %CV of ≤12.5% for control samples. Analyses of bococizumab ADAs and bococizumab nAbs were provided by ICON Laboratory Services, Inc.
(Whitesboro, NY, USA). The methodologies for these assays have been described previously. 16 Samples with a bococizumab concentration > 1 μg/mL were not analyzed by using the nAb assay due to potential interference and were instead classified as "inconclusive."
Titers of anti-rHuPH20 antibodies within blood samples were determined by using a semiquantitative electrochemiluminescence immunoassay with a %CV of ≤16.9% for control samples, while antirHuPH20 nAbs were measured by using a semiquantitative, in vitro hyaluronidase enzymatic immunoassay. Analyses of anti-rHuPH20
antibodies were provided by Eurofins Pharma Bioanalytics Services US, Inc. (St. Charles, MO, USA), and analyses of anti-rHuPH20 nAbs were provided by MicroConstants, Inc. (San Diego, CA, USA). The methodologies for these assays have been described previously. 23 
| Data analysis 2.4.1 | PK parameters
Parameters serving as PK endpoints were the AUC inf , C max , median time to C max (T max ), terminal half-life (t ½ ), apparent clearance (CL/F), and apparent volume of distribution (V z /F) of bococizumab. All randomized and dosed subjects who had at least 1 recorded value for these PK parameters were included in the PK analysis population. Plasma samples with bococizumab concentrations below the lower limit of quantification were assigned a value of 0 for the statistical analysis.
Dose-normalized AUC inf , AUC last , and C max were analyzed by using an ANCOVA model with treatment as a fixed effect and BMI as a covariate.
Estimates of the adjusted means and corresponding 90% CIs were obtained from the model and exponentiated to provide estimates of the ratios between test and reference groups. Calculation of PK parameters was performed by using an internally validated software system (electronic noncompartmental analysis version 2.2.4), and statistical analysis was performed by using SAS® 9.4.
| PD parameters
Parameters serving as PD endpoints were the absolute and percent changes from baseline in LDL-C at Day 29 following administration of bococizumab, as well as the AUEC 85 for LDL-C. Additional measures included MaxE LDL-C and the time taken to reach MaxE LDL-C (T max,LDL-C ). PD parameters were analyzed by using an ANCOVA model with treatment as a fixed effect, and baseline LDL-C and BMI as covariates. Estimates of the adjusted means and corresponding 90% CIs were obtained from the model and exponentiated to provide estimates of the ratios between test and reference groups. Calculation of PD parameters and statistical analysis was performed by using SAS 9.4.
| Safety evaluations
Safety evaluations included the incidence and severity of treatmentemergent adverse events (AEs) and serious AEs (SAEs), the relationship of AEs and SAEs to study medication, and the incidence of abnormal and clinically relevant results from clinical laboratory tests, vital signs measurements, electrocardiograms, and physical examinations. Immunogenicity was assessed by monitoring the incidence and titer of bococizumab ADAs and rHuPH20 ADAs. A tiered ADA-testing strategy was used: All samples that were positive in the screening assay were confirmed for antibody specificity, with confirmed-positive samples fur-
ther characterized for titer and tested in the nAb assay if appropriate.
| Ethics statement
The final study protocol and informed consent documentation were reviewed and approved by the independent ethics committee at the participating investigational center. In addition to following all local regulatory requirements, the study was conducted in compliance with 3 | RESULTS
| Study population
Sixty healthy adult subjects were recruited and randomized equally among the 4 dosing groups (Table 1 ). All randomized subjects completed the study, and data from all 60 subjects were included in the PK, PD, and safety analyses. The study included more men than women (66.7% vs 33.3%), and most were of white race (91.7%). The 3.2 | PK profile of bococizumab with and without rHuPH20 co-mixture
The rate of absorption of bococizumab into the systemic circulation was similar across the 4 dosing groups, with median T max from 4.00 to 5.05 days ( Figure 1 and Table 2 ). The t ½ of bococizumab ranged from 6.59 to 7.77 days across the 4 dosing groups. The CL/F ranged from 0.67 to 0.80 L/day across the 3 dosing groups that received bococizumab co-mixed with rHuPH20, which was lower than the value observed in the group administered bococizumab 300 mg alone (1.02 L/day). The V z /F ranged from 7.04 to 7.59 L across the dosing groups that received bococizumab co-mixed with rHuPH20, which was also lower than the value observed in the group administered bococizumab 300 mg alone (10.15 L).
There was a dose-dependent increase in total plasma exposure to bococizumab across the dosing groups: Dose-normalized AUC inf showed a slightly supraproportional increase across the dosing groups that received bococizumab in co-mixture with rHuPH20, whereas FIGURE 1 Linear and semilogarithmic (inset) concentration-time profiles of bococizumab following a single subcutaneous dose of bococizumab alone or in co-mixture with rHuPH20. rHuPH20, recombinant human hyaluronidase AUC inf , area under the plasma concentration-time profile from time zero extrapolated to infinite time; CL/F, apparent clearance; C max , maximum plasma concentration; DN; dose-normalized to a 300-mg dose; rHuPH20, recombinant human hyaluronidase; T max , time to C max ; V z /F, apparent volume of distribution; t ½ , terminal half-life.
a Data are presented as geometric mean (% coefficient of variation), except T max data which are median (range) and t ½ data which are arithmetic mean ± standard deviation.
dose-normalized C max showed a slightly subproportional increase across these groups (Table 2) . Based on the dose-normalized AUC inf and C max values, plasma exposure to bococizumab was higher in the dosing groups that received bococizumab in co-mixture with rHuPH20 compared with the group administered bococizumab 300 mg alone.
Model-based estimates of the ratios between test and reference dosing groups in dose-normalized AUC inf , AUC last , and C max are shown in 
| PD effect of bococizumab with and without rHuPH20 co-mixture
The time at which the reduction in LDL-C was maximal (T max,LDL-C ) was approximately 21 days in the 3 dosing groups that received bococizumab 150 or 300 mg, while it was 28 days in the group administered bococizumab 450 mg + rHuPH20 (Figure 2 ). At Day 21, the group administered bococizumab 300 mg alone showed a greater mean percent reduction in LDL-C from baseline compared with the bococizumab 300 mg + rHuPH20 group (59.5% vs 52.2%, respectively; Table 4 ), but the mean percent reductions observed in these 2 groups at Day 29 were similar (49.6% vs 51.7%, respectively).
Ratios of the exponentiated means for AUEC 85 and MaxE LDL-C between test and reference groups are shown in 
| Safety
There were no deaths, severe AEs, or discontinuations due to an AE in this study (Table 6 ). Two SAEs of "arthralgia" and "condition aggravated," both of which were considered to be unrelated to study of LDL-C reductions in the two 300-mg dosing groups showed that co-mixture with rHuPH20 appeared to reduce the nadir of LDL-C reduction but prolong the duration of effect. Our data also show that study that included a slightly higher subcutaneous bococizumab dose of 200 mg. 9 The dosing group that received bococizumab 450 mg + rHuPH20 also showed increased bioavailability, but the magnitude and duration of the LDL-C response observed were consistent with what could be expected for this size of dose without rHuPH20 co-mixture, which indicated that the observed effect on PD parameters was not due to enhanced bioavailability.
The safety profile of bococizumab in the current study was consistent with that seen in previous studies and showed that a co-mixture of bococizumab and rHuPH20 was generally safe and well tolerated by healthy adults. 9, [11] [12] [13] [14] 16, 17 Overall, the most frequently reported AEs were injection-site erythema, injection-site bruising, and nasopharyngitis. All injection-site AEs were considered mild in severity, with their overall incidence being highest in the bococizumab 450 mg + rHuPH20 dosing group. The incidence of ADAs in our study was similar to the rate observed in the phase 1 study of bococizumab that investigated 3 different injection sites:
The incidence in this previous study was 30.7% (23/75 subjects), 11 while the rate we observed was 21.7%. The incidence of nAbs to bococizumab in the present study was higher than previously b A 36-year-old man in the bococizumab 300-mg group reported 2 nontreatment-emergent serious adverse events (SAEs) of "arthralgia" and "condition aggravated" (investigator reported terms: worsening knee pain due to previous meniscus tear). The subject had experienced intermittent knee pain since a knee injury more than 3 months prior to the administration of study medication and went on to have an arthroscopic meniscus repair. Both SAEs were considered unrelated to study medication by the investigator.
observed in the single-dose study that investigated 3 different injection sites (11.7% vs 5.3%), but it is important to note several differences in methodology: The injection-site study only included subjects with fasting LDL-C ≥ 130 mg/dL, only investigated bococizumab administered alone, and only involved a bococizumab dose of 150 mg, which was the dose level with which we observed no incidence of ADA development at all. The dosing groups and the number of subjects who developed ADAs were not of sufficient size to support a meaningful evaluation of the impact of immunogenicity on PK or PD parameters.
Our phase 1 study has some limitations. First, the participants in our study were not hypercholesterolemic and did not receive the study medication against a background of lipid-lowering therapy.
Therefore, the PK/PD behavior of bococizumab in our study may not have fully reflected the situation in patients eligible for treatment with a PCSK9 inhibitor. Second, the participating subjects received only a single dose of study treatment, and this does not reflect the PK, PD, or safety profiles that a chronic dosing paradigm would induce. Third, our results may not be representative for broader patient groups because the study was conducted at a single European center where more than 90% of the participants were of white race. Fourth, while the aim of including the bococizumab 450 mg + rHuPH20 dosing group was to assess the overall tolerability of this size of subcutaneous injection, one that is usually consid- larger-volume, 450-mg dose of bococizumab co-mixed with rHuPH20, was found to be tolerable and had a dose-proportional effect on LDL-C. The co-mixture of bococizumab and rHuPH20 was well tolerated and showed a safety profile that was consistent with previous studies of bococizumab.
